Our lab studies dysregulated signaling networks that are characteristic of cancer and disease. Specifically, we use proteomics and genomics to characterize adaptive responses of tumors to targeted kinase inhibitors.
My work has been focused on the adaptive responses and acquisition of resistance to targeted inhibitors in cancer.
